Semaglutides such as obesity and diabetes drugs, especially Wegovy and Ozempic, can reduce the risk of human dementia, according to a new study.
Researchers showed a promise to lower these drugs to reduce the risk of cognitive impairment.
Experts say further studies are needed to understand the influence of drugs on the brain and the mechanism of this potential protection effect.
The US study analyzed data from type 2 diabetes patients who take GLP-1 receptor agonist (GLP-1RA) or sodium-glucose co-manufacturer-2inHibitors (SGLT-2I).
SGLT-2I reduces glucose reorganization in the kidneys, while GLP-1RA, such as Semaglutide, works.
Semaglutide is available as WEGOVY and Ozempic injections and rybelsus tablets.
The results of this study show the potential connection between these drugs and low risk of dementia.
Wegovy was approved to solve the weight loss of NHS in 2023, and Ozempic and Rybelus can be used in health services as type 2 diabetes treatment.
The study surveyed 396,963 health records of OneFlorida+ Clinical Research Consortium between January 2014 and June 2023.
All patients were over 50 years old and type 2 diabetes. They did not diagnose Alzheimer’s disease and related dementia (ADRD).
Researchers compared GLP-1RA, SGLT-2I and other secondary glucose.
The analysis said, “GLP-1RA and SGLT2IS have been significantly related to the reduction of the risk of ADRD compared to other GLDs, and no differences were observed between the two drugs.”
Meanwhile, among GLP-1RA, “Three Luti seems promising to reduce the risk of ADRD”.
Researchers said, “This discovery is especially interesting given the existing research on the neurotrosis characteristics of Semaglutide.
Dr. Leah Mursaleen, head of the clinical research director of Alzheimer Research UK, said: “The results of this study are increasing evidence that GLP-1RA and SGLT-2 inhibitors can reduce the risk of dementia.
“We don’t know why this medicine offers protective effects, and we need more research to understand how it affects the brain.”
She added that the result is “interesting” but should consider whether other factors can affect the overall health, income or education.
Meanwhile, Ireland researchers suggested that GLP-1RA is related to the statistically significant decrease in dementia.
This study has reduced the risk of dementia or cognitive impairment by analyzing drugs such as SGLT2IS and GLP-1RAS, and 26 clinical trials, including about 165,000 patients, such as diabetes drug metformin and pioglita zone.
“GLP-1RA has been associated with statistically significant decrease in significant dementia on all causes, but most drugs have found that” there is no overall decrease in dementia due to all causes. “
Both studies have been published in the journal. Zama neurology.
Professor Tara Spires-Jones at the University of Edinburg, the group leader of the UK DEMENTIA RESEARCH Institute, and the British neurological science association, “ He said he was “encouraging” to use GLP-1RA to lower the risk of dementia.
“But even in these two powerful studies, there is a slightly conflicting result compared to SGLT2IS, which emphasizes the need for further research,” she added.
“It should be noted that these drugs have side effects and cannot prevent dementia.
“Studies have an important limit, including relatively short subsequent times. Future work will be important to understand how risk factors such as diabetes and obesity effectively develop the risk of dental floss and prevention strategies.”
Masud Husain, a professor of neurology and cognitive neuroscience at Oxford University, added: “For me, according to this new post-flavor analysis, the GLP-1 receptor agent, especially the three-gruide, can reduce the risk of dementia in type 2 diabetes.
“But we need data from the prospective test to provide more powerful evidence.
“The wider question of whether these drugs of people without diabetes can protect dementia are really interesting and focus on some ongoing clinical trials.”
